Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

S-531011

Copy Product Info
🥰Excellent

Synonyms:

Catalog No. T9901A-1004 Copy Product Info
🥰Excellent
S-531011 is a human IgG1 monoclonal antibody that targets CCR8. It reduces tumor-infiltrating CCR8+ Tregs and exhibits antitumor activity in CT26.WT and EMT6 tumor-bearing mouse models. S-531011 is useful for cancer immunotherapy research. The recommended isotype control is HumanIgG1kappa, Isotype Control.

S-531011

Pack SizePriceUSA StockGlobal StockQuantity
1 mgInquiryInquiryInquiry
5 mgInquiryInquiryInquiry
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Product Introduction

Bioactivity
Description
S-531011 is a human IgG1 monoclonal antibody that targets CCR8. It reduces tumor-infiltrating CCR8+ Tregs and exhibits antitumor activity in CT26.WT and EMT6 tumor-bearing mouse models. S-531011 is useful for cancer immunotherapy research. The recommended isotype control is HumanIgG1kappa, Isotype Control.
Reactivity
Human
Application
FACS
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Storage & Solubility Information
StorageStore at low temperature -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: